TRH (Protirelin)

What Is TRH (Protirelin)?

TRH (thyrotropin-releasing hormone), known by the generic name protirelin, is a hypothalamic tripeptide with the structure pyroglutamyl-histidyl-prolinamide (pGlu-His-Pro-NH2). It regulates the activity of cells in the anterior pituitary and also acts within the central and peripheral nervous systems ^[1].

Its name describes its classic role: it is the hypothalamic factor that signals the pituitary to release thyrotropin, also called thyroid-stimulating hormone (TSH). Older literature also refers to it as thyroliberin, TSH-releasing factor and thyrotropin-releasing factor. Protirelin is the name used for the synthetic peptide, which is identical to the native hormone.

TRH has been studied for more than five decades. Research spans pituitary-thyroid physiology, its activity as a neuromodulator outside the hypothalamus, the development of receptor-selective analogs, and a family of related “TRH-like” peptides found in peripheral tissues ^[1].

Chemical Structure and Molecular Identity

Protirelin has the molecular formula C16H22N6O4 and a molecular weight of 362.38 g/mol (PubChem CID 638678; CAS 24305-27-9). Its systematic name is 5-oxo-L-prolyl-L-histidyl-L-prolinamide.

Although TRH is only three residues long, neither end of the molecule is a free amino acid terminus:

• N-terminus: pyroglutamic acid (5-oxo-L-proline), a cyclized glutamate residue with no free amino group.
• Middle residue: L-histidine, whose imidazole side chain is the basic residue in the molecule.
• C-terminus: L-prolinamide, meaning the terminal carboxyl group is an amide.

Because of these two terminal modifications, the peptide cannot be written accurately as a plain one-letter sequence; it is usually written as pGlu-His-Pro-NH2. All three stereocenters have the natural L (S) configuration. PubChem lists a calculated XLogP of -2.5, consistent with a small, highly polar molecule, and the standard InChIKey XNSAINXGIQZQOO-SRVKXCTJSA-N.

Other computed descriptors fit the same picture: a monoisotopic exact mass of 362.170 Da, 26 heavy atoms, four hydrogen-bond donors, five hydrogen-bond acceptors, six rotatable bonds and a topological polar surface area of 150 square angstroms. The exact mass is the value used when confirming the peptide by high-resolution mass spectrometry.

The histidine position matters for identity: a family of closely related “TRH-like” peptides differs from TRH only at this middle residue, which is discussed further below.

Research History and Development

TRH has been reviewed in the scientific literature for more than five decades, first as a hypothalamic releasing factor and later as a neuropeptide with wider roles. Burgus and Guillemin reviewed the hypothalamic releasing factors in the Annual Review of Biochemistry in 1970 ^[2].

Clinical and physiological interest followed. By 1979, TRH tests of pituitary-thyroid function were being compared in a report published in the Lancet ^[3]. In 1981, a New England Journal of Medicine editorial titled “What does brain thyrotropin-releasing hormone do?” reflected growing attention to TRH outside its pituitary role ^[4], and a 1982 review of thyrotropin-releasing hormone appeared in the same journal ^[5]. A 1995 review in the Journal of Neurochemistry continued this line of work on TRH in the nervous system ^[6].

Later research moved in two directions. One examined whether protirelin’s activity on spinal motor function was relevant to amyotrophic lateral sclerosis (ALS) ^[7]. The other focused on medicinal chemistry: designing TRH analogs and mapping how they interact with TRH receptors, including analogs that bind selectively at a second receptor subtype ^[1].

Mechanisms Studied in Research

TRH acts through class A G-protein-coupled receptors (GPCRs). The discovery of a second receptor subtype, TRH-R2, prompted a search for analogs that can distinguish between the two subtypes ^[1].

Pituitary and thyroid axis

TRH regulates the activity of cells in the anterior pituitary ^[1], and its name reflects its classic action of stimulating thyrotropin release. TRH-like peptides, which replace the basic histidine of TRH with a neutral or acidic amino acid such as glutamic acid, phenylalanine, glutamine or tyrosine, have been proposed to act as a form of negative feedback on the pituitary and to participate in regulating thyroid status ^[8].

Energy balance

A 1998 review described how information on energy balance is fed back to the paraventricular nucleus of the hypothalamus, where interplay between TRH and corticotropin-releasing hormone (CRH) shapes thermogenesis and stress responses. The same review noted that inflammatory mediators implicated in anorexia suppress TRH strongly enough to override thyroid hormone feedback, and that TRH metabolism is affected by dietary changes ^[9].

Nervous system

Outside the hypothalamus, protirelin has been described as a neuromodulator ^[7]. Reviews of TRH-like peptides also discuss proposed neuroprotective and antidepressant functions of these peptides in the brain ^[8].

Key Findings From Published Studies

The published record on TRH is dominated by reviews of physiology and analog chemistry, plus experimental work on its neuromodulatory effects. Findings are summarized by evidence type below.

Animal studies

In neonatal male rats, castration lowered sensitivity to protirelin’s ability to potentiate the monosynaptic spinal reflex, and testosterone treatment restored that sensitivity. The authors described this as evidence of a sex-related specificity in protirelin’s effect ^[7].

Human clinical studies

Protirelin was investigated as a possible adjunct in ALS, but clinical studies were divided on its efficacy despite strong experimental findings. A 1989 review noted that these trials either did not identify patients’ sex or did not analyze results by sex, and argued that hormonal status should be accounted for in future work ^[7].

Related peptides and analogs

• TRH-like peptides have been reported in peripheral tissues including the gastrointestinal tract, placenta, neural tissue, the male reproductive system and certain endocrine tissues ^[8].
• One TRH-like peptide, pGlu-Glu-Pro-NH2 (pEEPam), has been described as a fertilization-promoting peptide, and TRH-like peptides have been linked to the proliferative capacity of prostatic tissue ^[8].
• Medicinal chemistry work has produced a range of TRH analogs, and a 2006 review described the identification of analogs that bind selectively at TRH-R2 as a recent breakthrough ^[1].

Physiology reviews

Review literature places TRH inside the hypothalamic networks that set energy balance. In this model, TRH in the paraventricular nucleus contributes to the regulation of food intake, satiety, thermogenesis and other autonomic responses, and its suppression by inflammatory mediators has been implicated in anorexia ^[9]. These are conclusions drawn from reviewing earlier experimental work rather than results of a single controlled study.

Because TRH differs from TRH-like peptides by a single residue, researchers typically confirm identity with HPLC purity data and mass spectrometry matching 362.38 g/mol.

Regulatory and Research Status

Protirelin is a recognized drug substance with an assigned International Nonproprietary Name and USAN, BAN and JAN listings. Its established clinical role has been diagnostic: it has been used in the TRH stimulation test to assess pituitary-thyroid function ^[3].

In the United States, a protirelin diagnostic product was previously approved by the FDA but is no longer marketed. Protirelin is not approved by the FDA as a treatment for any condition, including ALS, where clinical studies were divided on its efficacy ^[7].

The name protirelin applies to the defined tripeptide only. TRH analogs and TRH-like peptides are separate chemical entities with their own structures, and findings for one cannot be assumed to apply to the others ^[8].

Synthetic TRH used in laboratory work is supplied for research use only. Review literature from the 2000s and 2010s has focused on TRH receptor pharmacology, receptor subtype-selective analogs ^[1], and the biology of TRH-like peptides in peripheral tissues ^[8].